β-Amyloid oligomers in aging and alzheimer's disease

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is a fatal neurodegenerative disorder, and the most common cause of dementia in the elderly. The cause of AD is not known, but genetic evidence strongly supports the hypothesis that pathological aggregation of the β-amyloid protein (Aβ) triggers the disease process. AD has a long preclinical phase, lasting a decade or more. It is during this preclinical phase, before the irreversible neuron loss that characterizes the dementia phase of the disease, that therapies are most likely to be effective. If we are to block AD during the preclinical phase, we must identify the A.. species that are present before there are overt symptoms and that are associated with downstream markers of pathology. A specific soluble Aβ assembly, the putative dodecamer "Aβ*56," is present in the brains and cerebrospinal fluid of cognitively intact individuals and correlates with markers of synaptic dysfunction and neuronal injury. This assembly also correlates with memory dysfunction in multiple lines of transgenic mice that model the preclinical phase of AD. We suggest that Aβ*56 has a critical role during the earliest phase of AD and might serve as a molecular trigger of the disease.

Original languageEnglish (US)
Article numberarticle 28
JournalFrontiers in Aging Neuroscience
Volume5
Issue numberJUL
DOIs
StatePublished - Sep 12 2013

Fingerprint

Amyloid
Alzheimer Disease
Dementia
Serum Amyloid A Protein
Neurodegenerative Diseases
Transgenic Mice
Cerebrospinal Fluid
Pathology
Neurons
Wounds and Injuries
Brain

Keywords

  • 56
  • Alzheimer's disease
  • Oligomer
  • Preclinical alzheimer's disease
  • β-Amyloid

Cite this

β-Amyloid oligomers in aging and alzheimer's disease. / Zahs, Kathleen R; Ashe, Karen H.

In: Frontiers in Aging Neuroscience, Vol. 5, No. JUL, article 28, 12.09.2013.

Research output: Contribution to journalArticle

@article{5491e0db89924757841100d9d167340a,
title = "β-Amyloid oligomers in aging and alzheimer's disease",
abstract = "Alzheimer's disease (AD) is a fatal neurodegenerative disorder, and the most common cause of dementia in the elderly. The cause of AD is not known, but genetic evidence strongly supports the hypothesis that pathological aggregation of the β-amyloid protein (Aβ) triggers the disease process. AD has a long preclinical phase, lasting a decade or more. It is during this preclinical phase, before the irreversible neuron loss that characterizes the dementia phase of the disease, that therapies are most likely to be effective. If we are to block AD during the preclinical phase, we must identify the A.. species that are present before there are overt symptoms and that are associated with downstream markers of pathology. A specific soluble Aβ assembly, the putative dodecamer {"}Aβ*56,{"} is present in the brains and cerebrospinal fluid of cognitively intact individuals and correlates with markers of synaptic dysfunction and neuronal injury. This assembly also correlates with memory dysfunction in multiple lines of transgenic mice that model the preclinical phase of AD. We suggest that Aβ*56 has a critical role during the earliest phase of AD and might serve as a molecular trigger of the disease.",
keywords = "56, Alzheimer's disease, Aβ, Oligomer, Preclinical alzheimer's disease, β-Amyloid",
author = "Zahs, {Kathleen R} and Ashe, {Karen H}",
year = "2013",
month = "9",
day = "12",
doi = "10.3389/fnagi.2013.00028",
language = "English (US)",
volume = "5",
journal = "Frontiers in Aging Neuroscience",
issn = "1663-4365",
publisher = "Frontiers Research Foundation",
number = "JUL",

}

TY - JOUR

T1 - β-Amyloid oligomers in aging and alzheimer's disease

AU - Zahs, Kathleen R

AU - Ashe, Karen H

PY - 2013/9/12

Y1 - 2013/9/12

N2 - Alzheimer's disease (AD) is a fatal neurodegenerative disorder, and the most common cause of dementia in the elderly. The cause of AD is not known, but genetic evidence strongly supports the hypothesis that pathological aggregation of the β-amyloid protein (Aβ) triggers the disease process. AD has a long preclinical phase, lasting a decade or more. It is during this preclinical phase, before the irreversible neuron loss that characterizes the dementia phase of the disease, that therapies are most likely to be effective. If we are to block AD during the preclinical phase, we must identify the A.. species that are present before there are overt symptoms and that are associated with downstream markers of pathology. A specific soluble Aβ assembly, the putative dodecamer "Aβ*56," is present in the brains and cerebrospinal fluid of cognitively intact individuals and correlates with markers of synaptic dysfunction and neuronal injury. This assembly also correlates with memory dysfunction in multiple lines of transgenic mice that model the preclinical phase of AD. We suggest that Aβ*56 has a critical role during the earliest phase of AD and might serve as a molecular trigger of the disease.

AB - Alzheimer's disease (AD) is a fatal neurodegenerative disorder, and the most common cause of dementia in the elderly. The cause of AD is not known, but genetic evidence strongly supports the hypothesis that pathological aggregation of the β-amyloid protein (Aβ) triggers the disease process. AD has a long preclinical phase, lasting a decade or more. It is during this preclinical phase, before the irreversible neuron loss that characterizes the dementia phase of the disease, that therapies are most likely to be effective. If we are to block AD during the preclinical phase, we must identify the A.. species that are present before there are overt symptoms and that are associated with downstream markers of pathology. A specific soluble Aβ assembly, the putative dodecamer "Aβ*56," is present in the brains and cerebrospinal fluid of cognitively intact individuals and correlates with markers of synaptic dysfunction and neuronal injury. This assembly also correlates with memory dysfunction in multiple lines of transgenic mice that model the preclinical phase of AD. We suggest that Aβ*56 has a critical role during the earliest phase of AD and might serve as a molecular trigger of the disease.

KW - 56

KW - Alzheimer's disease

KW - Aβ

KW - Oligomer

KW - Preclinical alzheimer's disease

KW - β-Amyloid

UR - http://www.scopus.com/inward/record.url?scp=84883578547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883578547&partnerID=8YFLogxK

U2 - 10.3389/fnagi.2013.00028

DO - 10.3389/fnagi.2013.00028

M3 - Article

C2 - 23847532

AN - SCOPUS:84883578547

VL - 5

JO - Frontiers in Aging Neuroscience

JF - Frontiers in Aging Neuroscience

SN - 1663-4365

IS - JUL

M1 - article 28

ER -